mice were used in our experiments. Blood flow recovery was significantly delayed in PKR Ϫ/Ϫ vs. WT mice (Laser Doppler detection, n ϭ 9, P Ͻ 0.01), accompanied by 34% reduced CD31-positive stain in ischemic muscle 28 days after procedure (immunohistochemistry, n ϭ 9, P Ͻ 0.05). PKR expression decreased in the first 12 h and increased to peak at 24 h in human umbilical vein endothelial cells (HUVECs) in response to hypoxia (Western blot analyses, n ϭ 3, P Ͻ 0.05). Accordingly, phospho-PKR expression increased in HUVECs 24 h after treatment with hypoxia (Western blot analyses, n ϭ 3, P Ͻ 0.05). Inhibition of PKR (siRNA transfection) reduced microtubule formation (Matrigel tube formation, n ϭ 3, vs. control siRNA, P Ͻ 0.05) and migration (wound healing, n ϭ 3, vs. control siRNA, P Ͻ 0.05) by 33 and 59%, respectively. Vascular endothelial growth factor (VEGF) expression in ischemic muscle from PKR Ϫ/Ϫ mice was significantly decreased by 54% 1 day after procedure (n ϭ 3, P Ͻ 0.05, vs. WT) and by 63% 7 days after procedure (n ϭ 3, P Ͻ 0.01, vs. WT), respectively. At the same time, VEGF expression in HUVECs decreased by 21% (n ϭ 3, P Ͻ 0.05, PKR siRNA vs. control siRNA). These findings demonstrate that PKR mediates angiogenesis through a VEGF pathway, which may form the basis for future intervention of PAD.
peripheral artery disease; double-stranded RNA-activated protein kinase; angiogenesis; vascular endothelial cell growth factor PERIPHERAL ARTERY DISEASE (PAD) is a worldwide disease defined by the presence of a flow-limiting lesion in an artery that provides blood to the limb. The most common causes of such arterial stenosis or occlusion are atherosclerosis, thromboembolism, and vasculitis. The number of people with PAD has increased by nearly a quarter between 2000 and 2010 (8) . Although multiple therapeutic approaches have been developed, including stents, medications, and surgery, it remains difficult to cure this kind of disease.
Impairment of endothelium function and inhibition of angiogenesis are the main factors for development of PAD. Angiogenesis is the formation of new blood vessels from the existing vascular network that includes endothelial cells (ECs) proliferation, tube formation, and migration, involving several growth factors. The vascular endothelial cell growth factor (VEGF) family of proteins is probably the most important for angiogenesis.
Double-stranded (ds)RNA-activated protein kinase (PKR) is a ubiquitously expressed serine/threonine protein kinase that is initially identified as an innate, immune antiviral protein that is induced by interferon (IFN) (16) . It is one of the four mammalian kinases (the others are GCN2, PERK, and HRI) that phosphorylate eukaryotic initiation factor 2␣ (eIF2␣) in response to viral infections. In addition to dsRNA, PKR has been shown to be responsive to many other factors, e.g., endoplasmic reticulum (ER) stress (11, 20) and cytokines such as tumor necrosis factor (TNF)-␣ (17). Due to its intrinsic properties, PKR has been recently studied to document its novel role in inflammation (15) and metabolism (18) . In addition, PKR can regulate smooth muscle cell (SMC) proliferation (21) and adherent molecular expression of ECs (2) (19) , which indicate a potential role in vascular function. However, its role in angiogenesis is still unclear. In the present study, we examined the involvement of PKR in an animal hindlimb ischemia model, trying to clarify the role of PKR in mediating angiogenesis.
MATERIALS AND METHODS
Mice and hindlimb ischemia model. Animal care and experimental procedures were performed with approval from animal care committees of the Central South University of Pittsburgh; the protocol number is 12050510. C57BL/6 background mice were purchased from Jackson Laboratory (Jackson Mice). PKR Ϫ/Ϫ mice were kindly provided by Dr. Bryan Williams (Department of Cancer Biology, Cleveland Clinic, Cleveland, OH) and have been characterized previously (13) (31). Unilateral hindlimb ischemia was induced in both wild-type (WT) and PKR Ϫ/Ϫ mice as follows. Briefly, all animals were anesthetized with isoflurane inhalation. The proximal and distal portions of the femoral artery and the distal portion of the saphenous artery were ligated. The arteries and all side branches were dissected free and excised. The skin was closed with 5-0 surgical sutures. A Laser Doppler imaging (LDI) system PeriScan PIM3 (Perimed) was used to measure hindlimb blood perfusion before and immediately after surgery and then at 7-day intervals until the end of the study, for a total follow-up of 28 days after surgery. Before imaging, excess fur was removed from the limbs using depilatory cream, and mice were placed on a heating plate at 40°C. To avoid the influence of ambient light and temperature, results were expressed as the ratio between perfusion in the right (ischemic) and left (nonischemic) hindlimbs.
Immunohistochemistry assays. Immunohistochemistry assays were processed as previously described (4) . Briefly, 4 wk after surgery, mice were killed by CO 2 overinhalation. The ischemic thigh muscles were embedded in paraffin. All the specimens were routinely fixed overnight in 4% buffered formalin and embedded in paraffin. Fourmicrometer sections of tissue samples were subjected to immunoperoxidase biotin-avidin reaction using the labeled streptavidin biotin method to determine CD31 expression. The sections for immunohistochemistry were cut and mounted on slides, allowed to dry overnight at 37°C to ensure optimal adhesion, dewaxed, rehydrated, and treated with 0.3% H 2O2 in methanol for 10 min to block endogenous peroxidase. The sections were incubated at room temperature for 30 min with the following antibodies: purified rat anti-mouse CD31 [dilution 1:30, monoclonal (IgG2a); BD Bioscience]. Finally, slides were counterstained with hematoxylin. Capillary density was measured by counting six random high-power (magnification ϫ200) fields for a minimum of 200 fibers from each ischemic and nonischemic limb on an inverted light microscope and were expressed by the number of CD31-positive cells per square millimeter.
Hypoxia of HUVECs. Hypoxic conditions were created by placing the cells into a modular incubator chamber (Billups-Rothenburg) flushed with a hypoxic gas mixture containing 1% O 2, 5% CO2, and 94% N2. A mass spectrometer was used to verify gas composition in the inner chamber. Cells were subcultured on multiwell plates, grown to confluence, serum deprived for 24 h, and placed inside the chamber.
PKR gene silencing of HUVECs by siRNA. Inhibition of PKR mRNA translation was performed using siRNA targeted to PKR mRNA (Santa Cruz Biotechnology) as described previously, with minor modifications (25) . Described briefly, 2 ϫ 10 5 HUVECs were seeded in six-well plates. HUVECs at 60 -70% confluence were transfected with Lipofectamine 2000 (Invitrogen) and PKR-siRNA (at a final concentration of 100 pmol/ml) or control siRNA (Santa Cruz Biotechnology) in the absence of antibiotics for 5 h. Following a washing in phosphate-buffered saline(PBS), the medium was replaced with EGM-2 for an additional 24 h. Cell protein was collected for analysis. Specific silencing was confirmed by Western blot. Cell viability was tested via MTS assay.
Tube formation assay. Tube formation assay was performed as previously described (29) . A 96-well flat-bottom plate was coated with 50 l of Matrigel (BD Biosciences) per well and kept at 37°C for 1 h to promote gelling. Cells (2 ϫ 10 4 ) in 100 l of medium were seeded into each Matrigel-coated well. Cells were then incubated at 37°C in 5% CO2. The center of each well was photographed at 12 h using an inverted microscope (Nikon) at ϫ40 magnification.
Wound healing migration assay. Wound healing migration assay was performed as previously described (23) . HUVECs were seeded onto six-well plates. Cells were grown to confluence and serum starved overnight. The monolayer of cells was scratched by a 200-l sterile pipette tip. Images were obtained at 0 and 24 h after treatments. The wound area was determined using Image J, and wound healing was calculated as a percentage of decrease in wound area.
Cell proliferation assay. For determination of viable cell number, HUVECs transfected with PKR siRNA 24 h later were plated in 96-well plates at a density of ϳ6,000 cells/well in the medium. After overnight starvation (2% serum), cells were treated with agents as indicated in each experiment. The number of viable cells was determined using a CellTiter Aqueous One Solution Cell Proliferation Assay kit (Promega) according to the manufacturer's instructions.
Western blotting. Western blotting was performed as described previously (7). Proteins were extracted from cultured cells using CelLytic MT Cell Lysis Reagent (Sigma) and separated on SDS- polyacrylamide gels. Proteins were probed with the following antibodies: anti PKR, p-PKR, (1:200, Santa Cruz Biotechnology); VEGF (1:1,000, Abcam); actin, and GAPDH (1:1,000, Santa Cruz Biotechnology) were used as internal controls. The blots were scanned with an Odyssey imager (LI-COR Biosciences), and band intensity was determined with the Quantity One System (Bio-Rad).
Statistical analysis. All values were expressed as means Ϯ SE. Student's t-test was used to determine the statistical significance of the data obtained and to compare the means between two groups. Repeatedmeasures ANOVA was used to assess the improvement in perfusion over time within groups. A P value of Ͻ0.05 represented a statistically significant difference.
RESULTS

Impaired blood flow recovery with reduced capillary density was found in surviving skeletal muscle of PKR
Ϫ/Ϫ mice after ischemia. To investigate the role of PKR in angiogenesis, blood flow recovery of ischemic skeletal muscle in both WT and PKR Ϫ/Ϫ mice was evaluated at 1, 7, 14, 21, and 28 days after ischemia by a laser speckle blood flow imager. In WT mice, blood flow decreased precipitously until 1 day after ischemic surgery; however, blood flow recovered promptly and returned to almost nonischemic hindlimb levels on day 28. In contrast, the recovery of blood perfusion in surviving ischemic hindlimbs of PKR Ϫ/Ϫ mice was poor throughout the follow-up period, and the ratio of ischemic to nonischemic laser speckle blood flow was persistently lower in PKR Ϫ/Ϫ mice than in WT mice (Fig. 1, A and B) . At 4 wk after surgery, capillary vessels identified by CD31 staining were markedly decreased (by 34%) in the ischemic muscle of PKR Ϫ/Ϫ mice, compared with WT mice (Fig. 1, C and D) .
PKR expression increased in HUVECs after treatment with hypoxia. Since PKR plays an important role in ischemia-induced angiogenesis, as the evidence showed above, whether PKR is activated under hypoxic conditions should first be clarified. Here, we tested PKR and p-PKR expression after incubation with hypoxia. The results showed that PKR expression changed with time. It was decreased in the first 6 h, increased to peak at 24 h, and eventually decreased afterward ( Fig. 2A) . As the climax expression appears at around 24 h, we examined its activation form, p-PKR, after incubation with hypoxia for 24 h, and p-PKR was significantly increased (Fig. 2B) .
Angiogenic potency was attenuated in PKR-deficient HUVECs. To clarify the influence of PKR deficiency on the angiogenic potency of vascular endothelial cells, in vitro angiogenesis and migration assays were performed (Fig. 3, C-F) . Figure 3A shows the effective transfection of PKR siRNA. PKR expression was decreased by PKR siRNA at 100 and 200 pmol/ml by 95 and 94%, respectively. In vitro angiogenesis was evaluated by tube formation of HUVECs in Matrigel. Significantly impaired tube formation (33% reduced vs. control siRNA) was observed in PKR siRNA-transfected HUVECs (Fig. 3, C and D) . Migration was assayed by wound healing of HUVECs (0 and 24 h after scratch). Migration function was reduced by 59% in HUVECs transfected with PKR siRNAs (Fig. 3, E and F) .
PKR knockout blunts activation of the VEGF signaling pathway. To determine whether knockout of PKR was associated with a blunted response of VEGF expression, we next examined VEGF expression in HUVECs transfected with PKR siRNA (Fig.  4, A B ) and ischemic muscle (Fig. 4, C-F) with Western blot. Compared with muscle from C57 mice, VEGF expression was significantly decreased in muscle from PKR Ϫ/Ϫ mice on day 1 (Fig. 4, C and D) and day 7 (Fig. 4 , E and F) after ischemia by 54 and 63%, respectively. The VEGF expression in HUVECs was also decreased slightly (by 21%) after PKR siRNA transfection (Fig. 4, A and B) . These results indicate that PKR knockout or knockdown impairs the VEGF expression.
DISCUSSION
In the present study, we identified PKR as a novel modulator implicated in ischemia-related angiogenesis. We showed that the expression of PKR is markedly upregulated in HUVECs and is indispensible for endothelial cell proliferation, migration, and tube formation. Accordingly, we demonstrated that PKR inhibition impairs the angiogenesis caused by limb ischemia in mice. In vitro and in vivo studies both suggest that PKR plays a key role in angiogenesis. Furthermore, we have also shown that this antiangiogenic response of PKR inhibition is possible through a VEGF pathway.
PKR, one member of the eIF2␣ phosphorylating family, is a 551 (515 in mouse) amino acid protein consisting of two functionally distinct domains: an NH 2 -terminal dsRNA binding regulatory domain, and a COOH-terminal kinase catalytic domain. The dsRNA binding domain contains two dsRNA binding motifs (dsRBMs) of ϳ70 amino acid residues each (31) . Besides dsRNA and type I IFN (1), the traditional activator or inducer of PKR, it also can be induced by a variety of stress-associated responses and inflammation, including TNF-␣ and interleukin-1 (IL-1). In our study, PKR is activated in HUVECs after being incubated with hypoxia, and the expression increased most at 24 h. This is consistent with the published data: PKR may be activated by hypoxia via inflammation or the ER stress pathway. However, this is not an only a simple process; it is actually inhibited in the first several hours after hypoxia.
Once activated, PKR has two roles: first, to directly affect protein function by phosphorylation, and second, to activate transcription factors by modulating cellular signaling networks. Besides the most studied downstream target eIF-2␣ (30) (24), PKR can mediate the activation of signal transduction pathways by proinflammatory stimuli, including bacterial lipopolysaccharide (LPS), TNF-␣, and IL-1 inflammatory cytokines (9, 26) .
Angiogenesis is the physiological process through which new blood vessels form from preexisting vessels. Endothelial cells, which form the inner lining of blood vessels, play a pivotal role in this process. Although PKR can be activated in endothelial cells by dsRNA, TNF-␣, and cell stress, the roles of PKR in endothelial functions are rarely studied, and the only little existing research seems to focus on adhesion molecule regulation mechanisms (2) (19) .
PKR can mediate the expression of VCAM-1 induced by poly(I).poly(C) in endothelial cells, and the induction of Eselectin expression by dsRNA and TNF-␣ is attenuated in murine aortic endothelial cells derived from PKR-null mice. In our study, endothelial cell function, including proliferation, migration, and tube formation, was inhibited after being transfected with PKR siRNA, which may account for the impair- Fig. 3 . Functions including tube formation and migration of HUVECs were tested after transfected with PKR siRNA. A: representative Western blot of PKR expression in HUVECs after being transfected with PKR siRNA at different concentration. B: PKR expression was decreased by PKR siRNA at 100 and 200 pmol/ml by 95 and 94%, respectively (n ϭ 3, *P Ͻ 0.05). C: in vitro angiogenesis was evaluated by tube formation of HUVECs in Matrigel. D: significantly impaired tube formation (33% reduced vs. control siRNA) was observed in PKR siRNA-transfected HUVECs. E: wound healing migration assay was tested in HUVECs (0 and 24 h after scratch). F: migration function was reduced by 59% in HUVECs transfected with PKR siRNAs (vs. control siRNA, n ϭ 3, *P Ͻ 0.05).
ment of blood flow reperfusion in ischemic limb. To some extent, this novel role of PKR in endothelial cell migration is consistent with PKR-mediated VCAM-1, E-selectin regulation, or other unknown adhesion molecules. Considerable evidence indicates that PKR controls cell growth and consequently usually functions as an inhibitor of cell proliferation. For instance, PKR mediates heparin-induced SMC antiproliferation through the regulation of STAT1 (10). However, further studies have shown a more complex function in cell proliferation (6, 26) . Besides the PKR-mediated proproliferation function of TNF, it may also play an important role in platelet-derived growth factor-induced cell proliferation via a different pathway. So it is possible that PKR is an upstream regulator of activation of some transcription factor and as a common mediator of both growth-promoting and growthinhibitory signals. In our study, HUVEC proliferation is attenuated by PKR siRNA, which is partly consistent with recent studies and may indicate a novel role for PKR in regulation of HUVECs function.
Recently, Liu et al. found that transgenic PKR mice demonstrate a decreased proliferation of hematopoietic stem/progenitor cells (HSPCs), reduced hematopoietic colony formation, and increased sensitivity to apoptosis-inducing cell stress, while PKR knockout mice have increased numbers of HSPCs and CFU activity and are more resistant to cell death. (14) Endothelial progenitor cells (EPCs) were characterized via expression of CD34 and VEGF receptor 2 (VEGFR2). Most EPCs reside in the bone marrow, supporting the integrity of vascular endothelium. As EPCs have been described as one kind of HSPCs sharing some markers on cell surface (27) , PKR may negatively regulate the proliferation of EPCs, which cannot promote angiogenesis. However, in our results, PKR inhibition can impair angiogenesis by affecting endothelial cells. So this can be attributed to the idea that PKR regulating angiogenesis mainly depends on endothelial cells.
Angiogenesis is a complicated process involved in many factors. Among the many factors implicated in angiogenesis, VEGF has been identified as one of the most potent and predominant (3) . VEGF can stimulate vascular endothelial cell growth, survival, and proliferation and eventually increase the number of capillaries in a given network. According to its powerful angiogenic ability, VEGF even has been applied in clinical therapy for some human ischemic diseases. Although PKR regulates many signaling pathways, the role of PKR-mediating angiogenesis is still unclear. Vumbaca et al. (28) identified that DRBP76, a kind of dsRNA-binding protein, plays a key role in VEGF mRNA stability and protein synthesis under hypoxia. At the same time, DRBP76 can be activated by PKR (22) . These findings provide an indirect link between PKR and VEGF. In our study, VEGF expression was reduced significantly in the ischemic muscle of PKR Ϫ/Ϫ mice on day 1 and day 7. Although the VEGF expression is much less on day 7 than on day 1, the residual VEGF can still promote reperfusion recovery slowly, and the same result can also be found in vitro. Apparently, preexisting evidence suggests a novel role of PKR-regulating VEGF expression, although the specific mechanism of PKR-mediated VEGF regulation is still unclear.
There are two kinds of PKR knockout mouse developed by now. One mouse, used by Nakamura et al. (18) , has target deletion of exon 12, which corresponds to the COOH terminus of the PKR (C-PKR Ϫ/Ϫ ), expresses a truncated mouse PKR protein and retains the dsRNA-binding properties of WT mice. The other mouse has a deletion of exons 2 and 3, corresponding to the NH 2 -terminal domain of PKR (N-PKR Ϫ/Ϫ ) and expresses a truncated protein that is defective in dsRNA binding but remains catalytically active. These mice show some different cell signaling responses that may depend on the catalytic activity of truncated PKR. In our animal model (N-PKR Ϫ/Ϫ mice), the reperfusion of ischemic hindlimb in mice was impaired. As the catalytically truncated PKR still exists in our mice, the role of PKR in angiogenesis may be caused by its noncatalytic segment.
Recently, PKR has been found to participate in inflammation-mediated metabolic disease and the release of HMGB1, a novel inflammation cytokine. In addition, PKR has also been found to serve as an intermediary in TLR signaling (12) . This novel proinflammation role of PKR affects many downstream signal transduction cascades, including JNK, IRF-3, and NF-B. One of the most studied is NF-B, which can be activated via IKK activation by PKR. Since NF-B signaling is a common pathway of angiogenesis, activating several angiogenic genes (5), it is possible that NF-B provides a potential link between PKR and VEGF, but further investigation is needed.
In conclusion, we have demonstrated that hypoxia is attributable to the aberrant expression and activation of PKR and that PKR inhibition impairs the angiogenesis caused by limb ischemia in mice. We have also shown that this antiangiogenic response is possible through a VEGF pathway. Therefore, PKR could be an attractive molecular target for treating PAD in the future.
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